Difference between revisions of "Part:BBa K1933004"
Soumo sarkar (Talk | contribs) (→MIT MAHE 2020) |
|||
| Line 7: | Line 7: | ||
| − | == | + | ==MIT_MAHE 2020== |
'''Summary''' | '''Summary''' | ||
| − | This is the single-chain variable fragments (scFv) of monoclonal antibodies Cetuximab. It is an epidermal growth factor receptor (EGFR) inhibitor, which specifically binds to the target antigen epidermal growth factor receptor (EGFR). With high affinity it can prevent ligand binding and activation of signal transduction. | + | This is the single-chain variable fragments (scFv) of monoclonal antibodies Cetuximab. It is an epidermal growth factor receptor (EGFR) inhibitor, which specifically binds to the target antigen epidermal growth factor receptor (EGFR). With high affinity it can prevent ligand binding and activation of signal transduction. |
==References== | ==References== | ||
Latest revision as of 18:39, 23 October 2020
constitutive promoter and RBS
This part, consisting of BBa_J23105 (constitutive promoter) and BBa_B0034, was created only as a registry entry.
MIT_MAHE 2020
Summary
This is the single-chain variable fragments (scFv) of monoclonal antibodies Cetuximab. It is an epidermal growth factor receptor (EGFR) inhibitor, which specifically binds to the target antigen epidermal growth factor receptor (EGFR). With high affinity it can prevent ligand binding and activation of signal transduction.
References
Jiang, K., Li, J., Yin, J., Ma, Q., Yan, B., Zhang, X., Wang, L., Wang, L., Liu, T., Zhang, Y., Fan, Q., Yang, A., Qiu, X., & Ma, B. (2015). Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials, 59, 77–87. https://doi.org/10.1016/j.biomaterials.2015.04.030
Kumar, M., Mani, P., Pratheesh, P., Chandra, S., Jeyakkodi, M., Chattopadhyay, P., Sarkar, D. P., & Sinha, S. (2015). Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes. Current molecular medicine, 15(4), 386–400. https://doi.org/10.2174/1566524015666150505155949
De Jong, W. H., & Borm, P. J. (2008). Drug delivery and nanoparticles:applications and hazards. International journal of nanomedicine, 3(2), 133–149. https://doi.org/10.2147/ijn.s596
Deepagan, V. G., Sarmento, B., Menon, D., Nascimento, A., Jayasree, A., Sreeranganathan, M., Koyakutty, M., Nair, S. V., & Rangasamy, J. (2012). In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine (London, England), 7(4), 507–519. https://doi.org/10.2217/nnm.11.139
Fadaeian, G., Shojaosadati, S. A., Kouchakzadeh, H., Shokri, F., & Soleimani, M. (2015). Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles. Iranian journal of pharmaceutical research : IJPR, 14(2), 395–405.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 7
Illegal NheI site found at 30 - 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Usage
We used this part for construction of ☆BBa_K1933100, BBa_K1933101, BBa_K1933102, BBa_K1933103 ☆BBa_K1933200, and BBa_K1933201.